Achiko AG (Achiko AG) Asset Impairment Charge : $0.00 Mil (TTM As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Achiko AG Asset Impairment Charge?

Achiko AG's Asset Impairment Charge for the six months ended in Jun. 2022 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00 Mil.

Achiko AG Asset Impairment Charge Historical Data

The historical data trend for Achiko AG's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG Asset Impairment Charge Chart

Achiko AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Asset Impairment Charge

Achiko AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Asset Impairment Charge	Get a 7-Day Free Trial			-	-	-	-	-

Achiko AG Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Achiko AG Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Achiko AG's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Achiko AG (Achiko AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (OTCPK:ACHKF) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tessinerplatz 7, Zurich, CHE, CH-8002

Website

https://www.achiko.com

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.